Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BI 3706674 + Cetuximab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BI 3706674 | BI-3706674|BI3706674 | KRAS Inhibitor 30 | BI 3706674 is a selective KRAS inhibitor, which non-covalently binds KRAS wild-type and mutant alleles, including G12A/C/D/V, G13D, and Q61H, potentially inhibiting Kras signaling and tumor growth (Cancer Res (2024) 84 (6_Supplement): 3317). | |
| Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 72 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA-approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR-positive colorectal cancer, and in combination with Braftovi (encorafenib) with or without mFOLFOX6 in patients with metastatic colorectal cancer with BRAF V600E (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|